查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2112459

數位偏頭痛治療設備：市場洞察、競爭格局和市場預測 - 2034 年

Digital Migraine Treatment Devices - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

概述：

  • 據估計，到 2025 年，數位偏頭痛治療設備市場價值將達到 1.425 億美元，預計到 2034 年將達到 6.124 億美元。這一成長的促進因素包括：非侵入性神經調節療法作為藥物療法的替代方案在臨床實踐中得到快速應用；FDA 批准的療法數量增加，適應症範圍擴大；以及應用程式控制的互聯療法擴大融入到常規偏頭痛管理中。
  • 全球數位偏頭痛治療設備市場預計在 2026 年至 2034 年的預測期內將以 17.6% 的複合年成長率成長。
  • 按產品類型分類，預計到 2025 年，穿戴式數位偏頭痛治療設備細分市場將佔 64% 的市場佔有率，從而推動數位偏頭痛治療設備市場的發展。
  • 按技術分類，預計到 2025 年，眶上刺激數位偏頭痛治療設備細分市場將以 31% 的市佔率引領數位偏頭痛治療設備市場。
  • 就連接方式而言，預計到 2025 年，支援藍牙的設備市佔率將達到 42%，引領數位偏頭痛治療設備市場。
  • 按應用領域分類，預計到 2025 年，慢性偏頭痛領域將佔市場佔有率的 53%，主導數位偏頭痛治療設備市場。
  • 預計到 2025 年，北美將以 45% 的銷售額引領全球數位偏頭痛治療設備市場，在全球區域市場佔有率中佔最高地位。

數位偏頭痛治療設備是一種利用受監管技術，無需藥物即可預防或治療急性偏頭痛發作的醫療設備，其主要原理是神經調控（最常見的是電刺激或磁刺激）。由於偏頭痛是一種高發生且治療效果往往不佳的神經系統疾病，許多患者希望避免急性期和輔助性治療藥物的副作用、禁忌症或過度使用的風險，因此，數位偏頭痛治療設備已成為一種臨床有效的非藥物輔助或替代療法，並被納入更廣泛的偏頭痛治療方案中。這些設備提供端到端的功能，包括透過智慧型手機應用程式進行神經調控、控制和記錄治療過程、基於雲端的症狀和使用情況追蹤，以及日益普及的與基層醫療醫師之間的連接和數據共用。市場按產品類型（穿戴式和手持式）、技術（眶上刺激、迷走神經刺激 (VNS)、單脈衝經顱磁刺激 (sTMS) 和枕神經刺激 (ONS)）以及連接方式（藍牙、Wi-Fi、智慧型手機連接和獨立式）進行細分。此外，就應用而言，這些療法可分為先兆徵兆偏頭痛和無徵兆偏頭痛，以及慢性偏頭痛和陣發性偏頭痛。就最終用戶而言，醫院和診所是主要用戶。在新型神經調節療法的臨床療效得到檢驗、獲得 FDA 批准、偏頭痛患病率不斷上升、患者和醫生對非藥物療法的偏好日益增強以及應用程式支持的互聯醫療生態系統不斷擴展等因素的推動下，數字偏頭痛治療設備正日益成為全球偏頭痛管理領域的主流組成部分。

數位偏頭痛治療設備市場的主要市場促進因素

  • 非侵入性神經調節療法的快速臨床和商業性擴張正在推動需求，預計到 2025 年，CEFALY 將成為美國退伍軍人治療偏頭痛最常用的神經調節設備，而 Theranica 公司的 Nerivio 正在擴大其適應症，包括兒童使用以及急性和預防性護理。
  • 隨著全球偏頭痛負擔日益加重，對非藥物療法的需求也不斷成長。根據全球疾病負擔分析報告估計，全球偏頭痛病例超過11億例，世界衛生組織（世衛組織）也將偏頭痛列為神經系統疾病負擔的主要原因之一。
  • 數位神經調節設備越來越受歡迎，因為它們可以避免急性及預防性藥物治療的副作用、藥物過度使用引起的頭痛風險以及禁忌症，導致患者和醫生越來越傾向於選擇非侵入性、無藥物的治療方法。
  • 加速法規核准和擴大適應症（例如 FDA 批准可在急性期和預防期使用的設備，以及擴大應用範圍至青少年和兒童患者群體）正在擴大目標患者群體，並推動市場接受度。
  • 隨著智慧型手機連接、支援藍牙的硬體和配套應用程式整合的進步，治療依從率正在提高，遠端監測正在成為可能，並且正在支援數據驅動的個人化偏頭痛管理。
  • 保險覆蓋範圍的擴大和醫療服務提供者的更多採用，正在拓寬患者的就醫途徑和報銷途徑，包括納入政府和退伍軍人醫療保健系統的處方藥清單和國家衛生服務供應目錄。
  • 偏頭痛的日益普遍、對非藥物療法的偏好不斷增強、監管的進步以及連網型設備的創新，所有這些因素都促使市場預計到 2034 年將保持強勁的兩位數成長。

推動數位偏頭痛治療設備市場成長的因素

市場促進因素

非侵入性神經調控技術的快速臨床和商業性化發展。

數位偏頭痛治療設備市場最強勁的驅動力是非侵入性神經調控療法作為主流偏頭痛治療方法在臨床和商業性的加速普及。預計到2025年，CEFALY Technology的眶上刺激裝置將成為美國退伍軍人中最常使用的偏頭痛神經調控設備。同時，Theranica的穿戴式遠距電神經運動設備Nerivio已獲得FDA批准，其適應症範圍擴大，可用於8歲及以上患者的急性期和預防性治療。隨著臨床證據的累積以及設備製造商不斷擴大其適應症範圍，涵蓋更多年齡層和偏頭痛亞型，這些設備的應用將從頭痛診所擴展到基層醫療機構和直接面對消費者的銷售管道，從而支撐市場持續成長至2034年。

全球偏頭痛負擔日益加重

全球偏頭痛疾病負擔日益加重，推動了對非藥物療法的需求。根據「2021年全球疾病負擔」分析，全球估計有超過11億例偏頭痛病例，並造成超過4,300萬個與偏頭痛相關的失能調整後存活年（DALYs）。此外，世界衛生組織（WHO）報告稱，2021年約有31億人患有頭痛相關疾病，其中偏頭痛是神經系統疾病負擔的主要原因之一。隨著人們對偏頭痛對工作、學習和生活品質功能性影響的認知不斷提高，患者和臨床醫生都開始轉向使用數位神經調節設備來降低偏頭痛發作的頻率和嚴重程度，這直接擴大了市場潛在患者群體。

市場限制因素

儘管數位偏頭痛治療設備市場發展勢頭強勁，但仍面臨諸多限制因素。與學名藥相比，設備和治療的高昂成本給無保險患者和自費患者帶來了沉重的經濟負擔，尤其是在對價格敏感的新興市場。不同地區醫保報銷政策的不一致和不斷變化，給製造商和患者都帶來了不確定性，許多國家的醫療保健系統缺乏針對神經調節設備的明確醫保覆蓋標準。雖然臨床證據正在增加，但與數十年來支持藥物治療偏頭痛的數據相比仍然有限，一些設備的實際療效也因與安慰劑對照試驗的結果相比而受到質疑。設備相關風險，例如皮膚刺激、不適、不便以及療效的局限性，都可能阻礙患者堅持治療。新型神經調節療法的法規核准流程可能漫長而昂貴。此外，過去的市場退出案例，包括2020年一家早期單脈衝經顱磁刺激（TMS）設備製造商的破產，凸顯了這個仍在發展中的設備領域固有的商業性脆弱性。基層醫療醫生和專科頭痛中心以外的患者對數位化偏頭痛治療的認知度較低，進一步阻礙了市場滲透。同時，針對同一患者族群，藥物創新（包括一類新型預防性藥物）的競爭依然存在。儘管偏頭痛負擔日益加重、非藥物療法的普及以及監管力度加大等潛在促進因素持續存在，但成本、保險報銷、證據和認知度等障礙仍然共同導致市場成長速度放緩。

目錄

第1章：數位偏頭痛治療設備市場：引言

  • 調查範圍
  • 市場區隔
  • 市場先決條件

第2章：數位偏頭痛治療設備市場：摘要整理

  • 市場概覽

第3章：數位偏頭痛治療設備市場：關鍵因素分析

  • 數位偏頭痛治療設備市場：市場促進因素
    • 非侵入性神經調控技術的擴展
    • 全球偏頭痛負擔日益加重
    • 人們對非藥物治療方案的興趣日益濃厚
    • 連網型設備的監理核准和創新
  • 數位偏頭痛治療設備市場：限制因素與挑戰
    • 高成本，且保險範圍存在不確定性。
    • 臨床證據和遵守用藥限制
    • 監管和意識方面的障礙
  • 數位偏頭痛治療設備市場：市場機遇
    • 擴大適應症範圍，適用於兒童和青少年
    • 新興市場和連網型設備的擴張

第4章：人工智慧、地緣政治、貿易與經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：波特五力分析

第7章：數位偏頭痛治療設備市場：評估

  • 依產品類型
    • 穿戴式數位偏頭痛治療設備
    • 攜帶式數位偏頭痛治療設備
    • 其他
  • 透過技術
    • 眶上刺激數位偏頭痛治療裝置
    • 迷走神經刺激（VNS）型數位偏頭痛治療設備
    • 採用單脈衝經顱磁刺激的數位偏頭痛治療設備
    • 枕神經刺激（ONS）數位偏頭痛治療設備
  • 連結性別
    • 支援藍牙的設備
    • 支援 Wi-Fi 的設備
    • 智慧型手機連接裝置
    • 獨立設備
  • 用途別
    • 無徵兆偏頭痛
    • 先兆性徵兆
    • 慢性偏頭痛
    • 發作性偏頭痛
  • 最終用戶
    • 醫院和診所
    • 專科神經科中心
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：數位偏頭痛治療設備市場：競爭格局

  • 市場集中度與結構
  • 競爭定位與市場佔有率分析（加值服務）

第9章：數位偏頭痛治療設備市場：新創企業資金籌措與投資趨勢

第10章：數位偏頭痛治療設備市場：公司概況與產品概況

  • CEFALY Technology
  • Theranica Bio-Electronics
  • electroCore, Inc.
  • Neurolief Ltd.
  • eNeura, Inc.
  • WAT Medical Technology
  • Soterix Medical, Inc.
  • Nu Eyne Co., Ltd.
  • Ybrain, Inc.
  • Shenzhen Dongdixin Technology Co., Ltd.

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0974

Digital Migraine Treatment Devices Market Summary

Overview:

  • The Digital Migraine Treatment Devices market is estimated at USD 142.50 million in 2025 and is projected to reach USD 612.40 million by 2034. Growth is anchored in the rapid clinical adoption of non-invasive neuromodulation as a drug-free alternative to pharmacological migraine care, expanding FDA clearances and label extensions, and growing integration of connected, app-controlled therapy into everyday migraine management.
  • The global Digital Migraine Treatment Devices market is growing at a CAGR of 17.6% during the forecast period from 2026 to 2034.
  • By product type, the wearable digital migraine treatment devices segment dominated the Digital Migraine Treatment Devices market with a 64% share in 2025.
  • By technology, the supraorbital stimulation digital migraine devices segment dominated the Digital Migraine Treatment Devices market with a 31% share in 2025.
  • By connectivity, the Bluetooth-enabled devices segment dominated the Digital Migraine Treatment Devices market with a 42% share in 2025.
  • By application, the chronic migraine segment dominated the Digital Migraine Treatment Devices market with a 53% share in 2025.
  • North America dominated the global Digital Migraine Treatment Devices market revenue with a 45% share in 2025, representing the highest regional market share globally.

A digital migraine treatment device is a regulated, technology-enabled medical device that uses neuromodulation, most commonly electrical or magnetic stimulation, to prevent or acutely treat migraine attacks without pharmaceutical intervention. Because migraine is a highly prevalent and often under-treated neurological disorder, and because many patients seek to avoid the side effects, contraindications, or overuse risk associated with acute and preventive medications, digital migraine treatment devices have emerged as a clinically validated, drug-free adjunct or alternative within the broader migraine care pathway. These devices provide end-to-end functionality spanning nerve stimulation delivery, smartphone app control and treatment logging, cloud-based symptom and usage tracking, and, increasingly, connected data sharing with treating physicians. The market is organized by product type across wearable and handheld form factors; by technology, including supraorbital stimulation, vagus nerve stimulation (VNS), single-pulse transcranial magnetic stimulation (sTMS), and occipital nerve stimulation (ONS); by connectivity across Bluetooth-enabled, Wi-Fi-enabled, smartphone-connected, and standalone devices; by application across migraine with and without aura and chronic and episodic migraine; and by end-user, led by hospitals and clinics. Driven by the clinical validation and FDA clearance of new neuromodulation modalities, rising migraine prevalence, growing patient and physician preference for non-pharmacological options, and the expansion of connected, app-enabled care ecosystems, digital migraine treatment devices have become an increasingly mainstream component of the global migraine management landscape.

Digital Migraine Treatment Devices Market Key Growth Drivers

  • The rapid clinical and commercial expansion of non-invasive neuromodulation therapies is driving demand, with CEFALY becoming the most frequently prescribed neuromodulation device for migraine among U.S. veterans in 2025 and Theranica's Nerivio expanding into pediatric and dual-use acute-and-preventive indications.
  • The rising global migraine burden is expanding demand for non-pharmacological treatment options, with Global Burden of Disease analyses estimating more than 1.1 billion prevalent migraine cases worldwide and the World Health Organization ranking migraine among the leading causes of neurological disease burden.
  • Growing patient and physician preference for drug-free, non-invasive treatment options is expanding adoption, as digital neuromodulation devices avoid the side effects, medication-overuse headache risk, and contraindications associated with acute and preventive pharmacotherapy.
  • Accelerating regulatory clearances and expanded indications, including FDA clearance of dual-use acute-and-preventive devices and expansion into adolescent and pediatric populations, are broadening the eligible patient base and increasing commercial adoption.
  • Increasing integration of smartphone connectivity, Bluetooth-enabled hardware, and companion apps is improving treatment adherence, enabling remote monitoring, and supporting personalized, data-driven migraine management.
  • Expanding payer coverage and institutional adoption, including inclusion in government and veteran health system formularies and national health service supply catalogues, is broadening patient access and reimbursement pathways.
  • The convergence of rising migraine prevalence, non-pharmacological treatment preference, regulatory momentum, and connected-device innovation is expected to sustain strong double-digit growth in the market through 2034.

Key Companies in Digital Migraine Treatment Devices Market

The competitive landscape is led by the following active manufacturers:

  • CEFALY Technology
  • Theranica Bio-Electronics
  • electroCore, Inc.
  • Neurolief Ltd.
  • eNeura, Inc.
  • WAT Medical Technology
  • Soterix Medical, Inc.
  • Nu Eyne Co., Ltd.
  • Ybrain, Inc.
  • Shenzhen Dongdixin Technology Co., Ltd.

Factors Contributing to the Growth of the Digital Migraine Treatment Devices Market

Market Drivers

Rapid Clinical and Commercial Expansion of Non-Invasive Neuromodulation

The most powerful driver of the Digital Migraine Treatment Devices market is the accelerating clinical and commercial adoption of non-invasive neuromodulation as a mainstream migraine therapy. CEFALY Technology's supraorbital stimulation device became the most frequently prescribed neuromodulation device for migraine among U.S. veterans in 2025, while Theranica's Nerivio remote electrical neuromodulation wearable has expanded its FDA clearance to include dual-use acute and preventive treatment in patients as young as eight years old. As clinical evidence accumulates and device manufacturers broaden approved indications across age groups and migraine subtypes, adoption is extending from specialty headache clinics into primary care and direct-to-consumer channels, anchoring sustained market growth through 2034.

Rising Global Migraine Burden

The growing global burden of migraine is expanding demand for non-pharmacological treatment alternatives. Global Burden of Disease 2021 analyses estimate more than 1.1 billion prevalent migraine cases and over 43 million migraine-related disability-adjusted life years worldwide, while the World Health Organization reports that headache disorders affected roughly 3.1 billion people in 2021, with migraine ranking among the leading causes of neurological disease burden. As awareness of migraine's disabling impact on work, education, and quality of life increases, both patients and clinicians are turning to digital neuromodulation devices to reduce attack frequency and severity, directly enlarging the addressable patient population for the market.

Market Restraints

Despite strong momentum, the Digital Migraine Treatment Devices market faces material constraints. High device and treatment costs relative to generic pharmacological alternatives limit affordability for uninsured and out-of-pocket patients, particularly in price-sensitive emerging markets. Inconsistent and evolving reimbursement policies across geographies create uncertainty for both manufacturers and patients, and many national health systems have yet to establish clear coverage pathways for neuromodulation devices. Clinical evidence, while growing, remains more limited than the decades of data supporting pharmacological migraine therapies, and some devices have faced questions regarding real-world effectiveness relative to sham-controlled trial results. Device-related risks, including skin irritation, discomfort, and treatment discontinuation due to inconvenience or perceived limited efficacy, can constrain sustained adherence. Regulatory pathways for novel neuromodulation modalities can be lengthy and costly, and past market exits, including the 2020 bankruptcy of an early single-pulse transcranial magnetic stimulation device maker, illustrate the commercial fragility that can accompany a still-maturing device category. Limited awareness of digital migraine treatment options among primary care physicians and patients outside specialty headache centers further constrains market penetration, while competition from pharmacological innovations, including newer classes of preventive medications, continues to compete for the same patient population. Together, these cost, reimbursement, evidentiary, and awareness barriers temper the pace of growth, even as the underlying drivers of rising migraine burden, non-pharmacological preference, and regulatory momentum remain firmly intact.

Digital Migraine Treatment Devices Market Segment Analysis

The digital migraine treatment devices market by product type (wearable digital migraine treatment devices, handheld digital migraine treatment devices, others), technology (supraorbital stimulation digital migraine devices, vagus nerve stimulation (vns) digital migraine devices, single-pulse transcranial magnetic stimulation digital migraine devices, occipital nerve stimulation (ons) digital migraine devices, others), connectivity (bluetooth-enabled devices, wi-fi-enabled devices, smartphone-connected devices, standalone devices), application (migraine without aura, migraine with aura, chronic migraine, episodic migraine, others), end-users (hospitals and clinics, specialty neurology centers, others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Product Type

Dominant Subsegment: Wearable Digital Migraine Treatment Devices.

The wearable digital migraine treatment devices segment accounted for 64% of the Digital Migraine Treatment Devices market in 2025. Wearable devices, including forehead headbands, upper-arm bands, and combined head-worn systems, are the leading product type because they enable both preventive daily use and acute on-demand treatment while allowing patients to continue normal activity during a session. Devices such as CEFALY's supraorbital headband, Theranica's Nerivio upper-arm wearable, and Neurolief's Relivion MG head-worn system have secured broad FDA clearances spanning acute and preventive indications and pediatric use, driving adoption across specialty headache clinics, primary care, and direct-to-consumer channels. The convenience, discretion, and connected-app integration of wearable form factors, combined with growing physician familiarity and payer recognition, sustain the segment's leadership. Handheld devices, led by electroCore's gammaCore vagus nerve stimulator, remain an important complementary category for acute, on-demand treatment, but the recurring daily-use pattern and dual-use clinical positioning of wearables secure their leadership across the forecast period.

By Technology

Dominant Subsegment: Supraorbital Stimulation Digital Migraine Devices.

The supraorbital stimulation digital migraine devices segment accounted for 31% of the Digital Migraine Treatment Devices market in 2025. Supraorbital stimulation, delivered via external trigeminal nerve stimulation (e-TNS), is the leading technology because it was the first neuromodulation modality to receive FDA approval for migraine and has since expanded from prevention-only to dual acute-and-preventive use, giving it the longest clinical track record, deepest physician familiarity, and broadest installed base of any modality. CEFALY Technology's device has been recognized as the most frequently prescribed neuromodulation device for migraine within the U.S. Veterans Health Administration system, reinforcing the segment's institutional credibility. Vagus nerve stimulation (VNS) devices, led by electroCore's gammaCore, hold a substantial share on the strength of dual migraine and cluster headache indications, while remote electrical neuromodulation and combined occipital-trigeminal stimulation platforms are expanding quickly on strong pediatric and dual-use clinical data. Single-pulse transcranial magnetic stimulation, the first FDA-cleared device category, remains a smaller niche following commercial disruption among early entrants. Despite rapid growth in newer modalities, the scale and evidentiary depth of supraorbital stimulation secure its leadership across the forecast period.

Digital Migraine Treatment Devices Market Region Analysis

Dominant Region: North America

North America accounted for 45% of the global Digital Migraine Treatment Devices market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high diagnosed migraine prevalence, a mature specialty headache-care infrastructure, clear FDA regulatory pathways, and expanding institutional and payer adoption, particularly in the United States. North America hosts the largest concentration of clinically validated device manufacturers and the deepest base of FDA-cleared products, and patients benefit from established reimbursement channels including Veterans Health Administration formulary inclusion. The commercial momentum of devices such as CEFALY and Nerivio, combined with growing physician familiarity and direct-to-consumer marketing, drives substantial adoption. Continued FDA clearances for expanded indications and pediatric populations, alongside major pharmaceutical and medtech companies monitoring the neuromodulation space, reinforce the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Digital Migraine Treatment Devices market. The region's elevated CAGR is driven by rising diagnosed migraine prevalence, expanding neurology and headache-care infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. South Korean manufacturers including Ybrain and Nu Eyne are advancing next-generation neuromodulation platforms domestically, China's Shenzhen Dongdixin Technology is scaling regional device manufacturing, and Japan and Australia are expanding specialty headache-clinic networks. Government healthcare investment, growing awareness of non-pharmacological pain management, and rising disposable income supporting out-of-pocket device purchases are accelerating adoption, while regional manufacturers increasingly pursue international regulatory clearances to compete globally. The combination of high unmet need, domestic device innovation, and healthcare infrastructure build-out positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 45% of the global Digital Migraine Treatment Devices market revenue in 2025. The United States dominates on the strength of its specialty headache-care infrastructure, FDA regulatory clarity, and institutional adoption through channels including the Veterans Health Administration, while continued label expansions and direct-to-consumer marketing reinforce its leadership.

Europe

Europe is a large and advanced regional market, supported by CE mark regulatory pathways, positive national health technology assessments such as the UK National Institute for Health and Care Excellence guidance on vagus nerve stimulation, and established specialty headache-clinic networks across Germany, France, the United Kingdom, Italy, and Spain. Belgium-based CEFALY Technology's home-market presence and expanding NHS Supply Chain listings reinforce the region's role in both device innovation and clinical adoption.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising migraine diagnosis rates, expanding neurology infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Domestic device innovation from South Korean and Chinese manufacturers, combined with international clearance pursuits, is accelerating regional market development.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding neurology and headache-care infrastructure, rising awareness of non-pharmacological migraine treatment options, and gradual regulatory alignment with FDA and CE mark standards are broadening access, while international distribution partnerships support the build-out of regional demand.

Digital Migraine Treatment Devices Market Competitive Landscape

The Digital Migraine Treatment Devices market is classified as Fragmented. A group of clinically established, first-mover players with broad regulatory clearances and deep real-world evidence, including CEFALY Technology, Theranica Bio-Electronics, and electroCore, anchor the top tier, while specialized and fast-scaling providers such as Neurolief, eNeura, WAT Medical Technology, Soterix Medical, Nu Eyne, Ybrain, and Shenzhen Dongdixin Technology compete through differentiated neuromodulation modalities, regional manufacturing strength, and emerging clinical indications, increasing competition across product categories.

The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Fragmented, with clinically established first movers leading and a growing field of specialized regional and technology-differentiated device makers.
  • Leading players: CEFALY Technology, Theranica Bio-Electronics, and electroCore anchor the top tier through first-mover regulatory clearances and the deepest real-world clinical evidence base.
  • Geographic reach: Leading players operate across North America, Europe, and expanding Asia-Pacific channels; CEFALY Technology, headquartered in Belgium with U.S. operations, exemplifies the transatlantic reach required for global distribution.
  • Product portfolio strength: Top players offer multiple device generations spanning acute, preventive, and dual-use indications, connected companion applications, and expanding pediatric and adolescent clearances.
  • Regulatory clearances: Breadth and recency of FDA clearances and CE marks, including expanded age range and dual-use acute-and-preventive indications, is a decisive competitive advantage.
  • Strategic partnerships: Institutional tie-ups, such as CEFALY's inclusion in Veterans Health Administration prescribing channels and electroCore's NHS Supply Chain listing, extend payer and provider reach.
  • Funding activity: Active venture financing, including Theranica's Series C round led by New Rhein Healthcare Investors, supports continued commercial expansion and pipeline development.
  • Manufacturing capabilities: Precision electrode and stimulation-hardware manufacturing, companion mobile application development, and cloud data infrastructure are key competitive moats.
  • Innovation focus: Expansion into pediatric and adolescent populations, dual-use acute-and-preventive indications, combined multi-nerve stimulation platforms, and AI-enabled personalized treatment algorithms.

Digital Migraine Treatment Devices Market Recent Developmental Activities

In 2026, CEFALY Technology unveiled a new brand identity alongside the CEFALY Migraine Relief app, giving users expanded tools to manage their migraine treatment and prevention routine. Strategic significance: Strengthens the connected-device ecosystem and reinforces CEFALY's leadership in supraorbital stimulation.

In November 2025, CEFALY Technology announced that CEFALY Connected became the most frequently prescribed neuromodulation device for migraine within the U.S. Veterans Health Administration, accounting for 53 percent of neuromodulation device orders in 2024. Strategic significance: Validates clinical adoption within a major institutional health system and reinforces CEFALY's leading market position.

Digital Migraine Treatment Devices Market Segmentation

Digital Migraine Treatment Devices Market by Product Type

  • Wearable Digital Migraine Treatment Devices
  • Handheld Digital Migraine Treatment Devices
  • Others

Digital Migraine Treatment Devices Market by Technology

  • Supraorbital Stimulation Digital Migraine Devices
  • Vagus Nerve Stimulation (VNS) Digital Migraine Devices
  • Single-Pulse Transcranial Magnetic Stimulation Digital Migraine Devices
  • Occipital Nerve Stimulation (ONS) Digital Migraine Devices
  • Others

Digital Migraine Treatment Devices Market by Connectivity

  • Bluetooth-Enabled Devices
  • Wi-Fi-Enabled Devices
  • Smartphone-Connected Devices
  • Standalone Devices

Digital Migraine Treatment Devices Market by Application

  • Migraine Without Aura
  • Migraine With Aura
  • Chronic Migraine
  • Episodic Migraine
  • Others

Digital Migraine Treatment Devices Market by End-User

  • Hospitals and Clinics
  • Specialty Neurology Centers
  • Others

Digital Migraine Treatment Devices Market by Geography

  • North America Digital Migraine Treatment Devices Market
  • United States Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • Canada Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • Mexico Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • Europe Digital Migraine Treatment Devices Market
  • Germany Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • United Kingdom Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • France Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • Italy Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • Spain Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • Rest of Europe Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • Asia-Pacific Digital Migraine Treatment Devices Market
  • China Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • Japan Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • India Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • Australia Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • South Korea Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Digital Migraine Treatment Devices Market
  • Middle East Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • Africa Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
  • South America Digital Migraine Treatment Devices Market Size in USD million (2023-2034)

Key Takeaways from the Digital Migraine Treatment Devices Market Report Study

  • Market size analysis for the current digital migraine treatment devices market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global digital migraine treatment devices market.
  • Various opportunities available for competitors in the digital migraine treatment devices market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current digital migraine treatment devices market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for digital migraine treatment devices market growth in the future?

Target audience who can benefit from this Digital Migraine Treatment Devices market report study

  • Digital migraine treatment devices product providers
  • Research organizations and consulting companies
  • Neurodegenerative disease therapeutics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in digital migraine treatment devices
  • Various end-users who want to know more about the digital migraine treatment devices market and the latest technological developments in the digital migraine treatment devices market.

Frequently Asked Questions:

Q1. What is the growth rate of the digital migraine treatment devices market?

The digital migraine treatment devices market is projected to expand at a CAGR of 17.6% during the forecast period from 2026-2034.

Q2. What is the market size of the digital migraine treatment devices market?

The digital migraine treatment devices market is estimated at USD 142.50 million in 2025 and is projected to reach USD 612.40 million by 2034.

Q3. Which region dominates the digital migraine treatment devices market?

North America dominated the Digital Migraine Treatment Devices market with a 45% share of global revenue in 2025, supported by a mature specialty headache-care infrastructure, clear FDA regulatory pathways, and expanding institutional and payer adoption. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the digital migraine treatment devices market?

The principal drivers are the rapid clinical and commercial expansion of non-invasive neuromodulation, with CEFALY becoming the most-prescribed neuromodulation device for migraine among U.S. veterans in 2025; the rising global migraine burden, with Global Burden of Disease analyses estimating more than 1.1 billion prevalent migraine cases worldwide; growing patient and physician preference for drug-free treatment options; accelerating regulatory clearances and expanded indications; and increasing integration of smartphone connectivity and companion applications.

Q5. Who are the major players in the digital migraine treatment devices market?

The major players include CEFALY Technology, Theranica Bio-Electronics, electroCore, Inc., Neurolief Ltd., eNeura, Inc., WAT Medical Technology, Soterix Medical, Inc., Nu Eyne Co., Ltd., Ybrain, Inc., and Shenzhen Dongdixin Technology Co., Ltd., among other active providers profiled in the Competitive Landscape section. CEFALY Technology, Theranica Bio-Electronics, and electroCore lead through first-mover regulatory clearances and the deepest real-world clinical evidence base.

Table of Contents

1. Digital Migraine Treatment Devices Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumptions

2. Digital Migraine Treatment Devices Market Executive Summary

  • 2.1 Market at a Glance

3. Digital Migraine Treatment Devices Market Key Factors Analysis

  • 3.1 Digital Migraine Treatment Devices Market Drivers
    • 3.1.1 Expansion of Non-Invasive Neuromodulation Adoption
    • 3.1.2 Rising Global Migraine Burden
    • 3.1.3 Growing Preference for Drug-Free Treatment Options
    • 3.1.4 Regulatory Clearances and Connected-Device Innovation
  • 3.2 Digital Migraine Treatment Devices Market Restraints and Challenges
    • 3.2.1 High Device Costs and Reimbursement Uncertainty
    • 3.2.2 Clinical Evidence and Adherence Limitations
    • 3.2.3 Regulatory and Awareness Barriers
  • 3.3 Digital Migraine Treatment Devices Market Opportunities
    • 3.3.1 Pediatric and Adolescent Indication Expansion
    • 3.3.2 Emerging-Market and Connected-Device Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1 United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Digital Migraine Treatment Devices Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Buyers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Digital Migraine Treatment Devices Market Assessment

  • 7.1 By Product Type
    • 7.1.1 Wearable Digital Migraine Treatment Devices
    • 7.1.2 Handheld Digital Migraine Treatment Devices
    • 7.1.3 Others
  • 7.2 By Technology
    • 7.2.1 Supraorbital Stimulation Digital Migraine Devices
    • 7.2.2 Vagus Nerve Stimulation (VNS) Digital Migraine Devices
    • 7.2.3 Single-Pulse Transcranial Magnetic Stimulation Digital Migraine Devices
    • 7.2.4 Occipital Nerve Stimulation (ONS) Digital Migraine Devices
    • 7.2.5 Others
  • 7.3 By Connectivity
    • 7.3.1 Bluetooth-Enabled Devices
    • 7.3.2 Wi-Fi-Enabled Devices
    • 7.3.3 Smartphone-Connected Devices
    • 7.3.4 Standalone Devices
  • 7.4 By Application
    • 7.4.1 Migraine Without Aura
    • 7.4.2 Migraine With Aura
    • 7.4.3 Chronic Migraine
    • 7.4.4 Episodic Migraine
    • 7.4.5 Others
  • 7.5 By End-Users
    • 7.5.1 Hospitals and Clinics
    • 7.5.2 Specialty Neurology Centers
    • 7.5.3 Others
  • 7.6 By Geography
    • 7.6.1 North America
      • 7.6.1.1 United States Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.1.2 Canada Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.1.3 Mexico Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
    • 7.6.2 Europe
      • 7.6.2.1 Germany Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.2.2 United Kingdom Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.2.3 France Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.2.4 Italy Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.2.5 Spain Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.2.6 Rest of Europe Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
    • 7.6.3 Asia-Pacific
      • 7.6.3.1 China Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.3.2 Japan Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.3.3 India Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.3.4 Australia Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.3.5 South Korea Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.3.6 Rest of Asia-Pacific Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
    • 7.6.4 Rest of World
      • 7.6.4.1 Middle East Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.4.2 Africa Digital Migraine Treatment Devices Market Size in USD million (2023-2034)
      • 7.6.4.3 South America Digital Migraine Treatment Devices Market Size in USD million (2023-2034)

8. Digital Migraine Treatment Devices Market Competitive Landscape

  • 8.1 Market Concentration and Structure
  • 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Digital Migraine Treatment Devices Market Startup Funding and Investment Trends

10. Digital Migraine Treatment Devices Market Company and Product Profiles

  • 10.1 CEFALY Technology
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Service Portfolio
    • 10.1.5 Strategic Initiatives / Entropy
  • 10.2 Theranica Bio-Electronics
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Portfolio
    • 10.2.5 Strategic Initiatives / Entropy
  • 10.3 electroCore, Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Portfolio
    • 10.3.5 Strategic Initiatives / Entropy
  • 10.4 Neurolief Ltd.
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Portfolio
    • 10.4.5 Strategic Initiatives / Entropy
  • 10.5 eNeura, Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Portfolio
    • 10.5.5 Strategic Initiatives / Entropy
  • 10.6 WAT Medical Technology
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Portfolio
    • 10.6.5 Strategic Initiatives / Entropy
  • 10.7 Soterix Medical, Inc.
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Portfolio
    • 10.7.5 Strategic Initiatives / Entropy
  • 10.8 Nu Eyne Co., Ltd.
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Portfolio
    • 10.8.5 Strategic Initiatives / Entropy
  • 10.9 Ybrain, Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Portfolio
    • 10.9.5 Strategic Initiatives / Entropy

10. Shenzhen Dongdixin Technology Co., Ltd.

    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Portfolio
    • 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Digital Migraine Treatment Devices Market in Global (2023-2034)
  • Table 2: Digital Migraine Treatment Devices Market in Global by Product Type (2023-2034)
  • Table 3: Digital Migraine Treatment Devices Market in Global by Technology (2023-2034)
  • Table 4: Digital Migraine Treatment Devices Market in Global by Connectivity (2023-2034)
  • Table 5: Digital Migraine Treatment Devices Market in Global by Application (2023-2034)
  • Table 6: Digital Migraine Treatment Devices Market in Global by End-Users (2023-2034)
  • Table 7: Digital Migraine Treatment Devices Market in Global by Geography (2023-2034)
  • Table 8: Digital Migraine Treatment Devices Market in North America (2023-2034)
  • Table 9: Digital Migraine Treatment Devices Market in the United States (2023-2034)
  • Table 10: Digital Migraine Treatment Devices Market in Canada (2023-2034)
  • Table 11: Digital Migraine Treatment Devices Market in Mexico (2023-2034)
  • Table 12: Digital Migraine Treatment Devices Market in Europe (2023-2034)
  • Table 13: Digital Migraine Treatment Devices Market in Germany (2023-2034)
  • Table 14: Digital Migraine Treatment Devices Market in United Kingdom (2023-2034)
  • Table 15: Digital Migraine Treatment Devices Market in France (2023-2034)
  • Table 16: Digital Migraine Treatment Devices Market in Italy (2023-2034)
  • Table 17: Digital Migraine Treatment Devices Market in Spain (2023-2034)
  • Table 18: Digital Migraine Treatment Devices Market in the Rest of Europe (2023-2034)
  • Table 19: Digital Migraine Treatment Devices Market in Asia-Pacific (2023-2034)
  • Table 20: Digital Migraine Treatment Devices Market in China (2023-2034)
  • Table 21: Digital Migraine Treatment Devices Market in Japan (2023-2034)
  • Table 22: Digital Migraine Treatment Devices Market in India (2023-2034)
  • Table 23: Digital Migraine Treatment Devices Market in Australia (2023-2034)
  • Table 24: Digital Migraine Treatment Devices Market in South Korea (2023-2034)
  • Table 25: Digital Migraine Treatment Devices Market in Rest of Asia-Pacific (2023-2034)
  • Table 26: Digital Migraine Treatment Devices Market in the Rest of the World (2023-2034)
  • Table 27: Digital Migraine Treatment Devices Market in the Middle East (2023-2034)
  • Table 28: Digital Migraine Treatment Devices Market in Africa (2023-2034)
  • Table 29: Digital Migraine Treatment Devices Market in South America (2023-2034)
  • Table 30: Competitive Landscape
  • Table 31: Startup Funding and Investment Trends

List of Figures

  • Figure 1: Digital Migraine Treatment Devices Market Drivers
  • Figure 2: Digital Migraine Treatment Devices Market Restraints
  • Figure 3: Digital Migraine Treatment Devices Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis (US, EU, Japan, China)
  • Figure 6: Porter's Five Forces Analysis
  • Figure 7: Competitive Analysis
  • Figure 8: Digital Migraine Treatment Devices Market in Global (2023-2034)
  • Figure 9: Digital Migraine Treatment Devices Market in Global by Product Type (2023-2034)
  • Figure 10: Digital Migraine Treatment Devices Market in Global by Technology (2023-2034)
  • Figure 11: Digital Migraine Treatment Devices Market in Global by Connectivity (2023-2034)
  • Figure 12: Digital Migraine Treatment Devices Market in Global by Application (2023-2034)
  • Figure 13: Digital Migraine Treatment Devices Market in Global by End-Users (2023-2034)
  • Figure 14: Digital Migraine Treatment Devices Market in Global by Geography (2023-2034)
  • Figure 15: Digital Migraine Treatment Devices Market in North America (2023-2034)
  • Figure 16: Digital Migraine Treatment Devices Market in the United States (2023-2034)
  • Figure 17: Digital Migraine Treatment Devices Market in Canada (2023-2034)
  • Figure 18: Digital Migraine Treatment Devices Market in Mexico (2023-2034)
  • Figure 19: Digital Migraine Treatment Devices Market in Europe (2023-2034)
  • Figure 20: Digital Migraine Treatment Devices Market in Germany (2023-2034)
  • Figure 21: Digital Migraine Treatment Devices Market in United Kingdom (2023-2034)
  • Figure 22: Digital Migraine Treatment Devices Market in France (2023-2034)
  • Figure 23: Digital Migraine Treatment Devices Market in Italy (2023-2034)
  • Figure 24: Digital Migraine Treatment Devices Market in Spain (2023-2034)
  • Figure 25: Digital Migraine Treatment Devices Market in the Rest of Europe (2023-2034)
  • Figure 26: Digital Migraine Treatment Devices Market in Asia-Pacific (2023-2034)
  • Figure 27: Digital Migraine Treatment Devices Market in China (2023-2034)
  • Figure 28: Digital Migraine Treatment Devices Market in Japan (2023-2034)
  • Figure 29: Digital Migraine Treatment Devices Market in India (2023-2034)
  • Figure 30: Digital Migraine Treatment Devices Market in Australia (2023-2034)
  • Figure 31: Digital Migraine Treatment Devices Market in South Korea (2023-2034)
  • Figure 32: Digital Migraine Treatment Devices Market in Rest of Asia-Pacific (2023-2034)
  • Figure 33: Digital Migraine Treatment Devices Market in the Rest of the World (2023-2034)
  • Figure 34: Digital Migraine Treatment Devices Market in the Middle East (2023-2034)
  • Figure 35: Digital Migraine Treatment Devices Market in Africa (2023-2034)
  • Figure 36: Digital Migraine Treatment Devices Market in South America (2023-2034)
  • Figure 37: Competitive Landscape
  • Figure 38: Startup Funding and Investment Trends